# US 2022/0064742 A1 · Association between integration of viral as hpv or hiv genomes and the severity and/or clinical outcome of disorders as hpv associated cervical lesions or aids pathology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064742 A1
- Document ID: US20220064742A1
- Status: Published application
- Kind: A1
- Application number: 17/298,395
- Filed: 2019-11-29
- Published: 2022-03-03
- Earliest claimed: 2018-11-30
- Assignees: Genomic Vision
- Applicants: Genomic Vision
- Inventors: Aaron BENSIMON; Stephanie BOUCHILLOUX; Frederic FER; Laurent CAVAREC; Florence MAHE
- Web page: https://patentgrep.com/patent/US20220064742A1

## CPC

- C12Q 1/708: {for papilloma}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6851: Quantitative amplification
- C12Q 1/703: {Viruses associated with AIDS}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention concerns the detection and the quantification of integrated nucleic acids of viruses and thus the detection and follow-up of reservoir cells harbouring such integrated viral genomes. One aspect of the invention is directed to a method for detecting a level of integrated viral DNA that includes removing episomal viral or vector nucleic acids from genomic DNA in a cell sample, and quantifying a number of integrations of viral DNA into the genomic DNA of the cells by a method of amplification of an integration region in the DNA sample; thereby detecting a level of integrated viral DNA in the genomic DNA from a cell sample, such as a biological sample containing HPV virus and DNA.

## Claims

### Claim 1

A method for detecting a level of integrated viral DNA or dormant DNA, such as proviral DNA, comprising:
removing episomal viral or vector nucleic acids from genomic DNA in a cell sample, and
quantifying a number of integrations of viral DNA into the genomic DNA of the cells by a method of amplification of an integration region in the DNA sample;
thereby detecting a level of integrated viral DNA in the genomic DNA from the cell sample; and
optionally, performing a method of amplification on episomal nucleic acids removed from the sample.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the amplification method is quantitative polymerase chain reaction (qPCR), fluorescent in situ hybridization (FISH) or molecular combing.

### Claim 3 (depends on 1)

The method of claim 1, wherein said step of removing comprises:
penneabilizing cell membranes in the cell sample by exposing the cells to an extracting salt solution for a time and under conditions sufficient to make the cellular membranes permeable to episomal viral or vector nucleic acids from the cells and for the episomal viral or vector nucleic acids to leak out of the cells into a medium,
separating the permeabilized cells from episomal viral or vector nucleic acids in the medium, and
performing qPCR on the separated permeabilized cells; and
optionally, isolating and performing qPCR on the episomal viral or vector nucleic acids in the medium.

### Claim 4 (depends on 1)

The method of claim 1, wherein said removing comprises:
embedding cells into an agarose plug having an agarose concentration ranging from about 0.5 wt % to 1.5 wt %,
infusing the plugs containing the embedded cells with a proteolytic enzyme for a time and under conditions sufficient to substantially digest cellular proteins,
washing the plugs for a time and under conditions sufficient to remove episomal nucleic acids,
extracting cellular genomic DNA caught in the plugs and
performing qPCR on the genomic DNA extracted from the washed agarose plugs.
performing qPCR on the separated penneabilized cells; and
optionally, isolating and performing qPCR on the nucleic acids washed out of the agarose plugs.

### Claim 5 (depends on 1)

The method of claim 1, comprising partially depleting episomal HPV nucleic acids by biotinylating episomal nucleic acids and binding them (strept)avidin, thus removing them from a mixture of genomic and episomal nucleic acids.

### Claim 6 (depends on 1)

The method of claim 1, comprising:
isolating nucleic acids from the cell sample using a plasmid purification column,
recovering genomic DNA from material eluting from the plasmid purification column, and
performing qPCR on the recovered genomic DNA; and, optionally,
isolating and performing qPCR on the material bound to the plasmid purification column

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell sample contains viral DNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cell sample contains HIV nucleic acids.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cell sample contains human papilloma virus (HPV) nucleic acids.

### Claim 10 (depends on 9)

The method of claim 9, further comprising detecting by PCR a ratio of DNA encoding HPV E2 ORF to DNA encoding HPV E6 ORF, especially by qPCR; wherein the ratio of DNA encoding E2 ORF to DNA encoding E6 ORF represents an amount of an episomal form in relation to an integrated form.

### Claim 11 (depends on 10)

The method of claim 10, wherein the ratio of E2 ORF to E6 ORF is determined by real-time PCR using a set of primers and probes described by Table 1.

### Claim 12 (depends on 9)

The method of claim 9, further comprising determining HPV viral load comprising determining a ratio between E6/E7 and beta globin, MSH2 or at least one other human gene target.

### Claim 13 (depends on 9)

The method of claim 9, further comprising detecting at least one biomarker that covers a junction between a disrupted host gene and at least part of an integrated HPV DNA.

### Claim 14 (depends on 9)

The method of claim 9, further comprising detecting at least one biomarker selected from the group consisting of MAPK10 (Gene ID: 5602), PTPN13 (Gene ID: 5783), NUDT15 (Gene ID: 55270), MED4 (Gene ID: 29079), ITM2B (Gene ID: 9445), RB1 (Gene ID: 5925), LPAR6 (Gene ID: 10161), RAB11A (Gene ID: 8766), RPL13A (Gene ID: 23521), ZNF341 (Gene ID: 84905), OFD1 (Gene ID: 8481), DHRS3 (Gene ID: 9249), TBC1D22B (Gene ID: 55633), AFF3 (Gene ID: 3899), CXCL6 (Gene ID: 6372), PF4V1 (Gene ID: 5197), IMMP2L (Gene ID: 83943), MMP12 (Gene ID: 4321), WDR20 (Gene ID: 91833), ALDHA1A (Gene ID: 216), TPRG1 (Gene ID: 285386), TUBD1 (Gene ID: 51174), MAST4 (Gene ID: 375449), LOC100132167, NFIX (Gene ID: 4784), CCAT1 (Gene ID: 100507056), GPR137B (Gene ID: 7107), RAB22A (Gene ID: 57403), C9orf3, MACROD2 (Gene ID: 140733), DACH1 (Gene ID: 1602), ATP10A (Gene ID: 57194), SPG11 (Gene ID: 80208), SORD (Gene ID: 6652), COL4A4 (Gene ID: 1286), GATSL1 (Gene ID: 729438), GATSL2 (Gene ID: 729438), MAP2 (Gene ID: 4133), EPN1 (Gene ID: 29924), ATXN3L (Gene ID: 92552), EGFL6 (Gene ID: 25975), and MAGI2 (Gene ID: 9863).

### Claim 15 (depends on 13)

The method of claim 13, wherein forward and reverse oligonucleotide primers that specifically amplify an integration junction between host genomic DNA and integrated HPV DNA are used to produce the biomarker.

### Claim 16 (depends on 13)

The method of claim 13, wherein the biomarker is human OFD1 (NG_008872.1) and is produced and the forward and reverse primers described by Table 2 are used to amplify an OFD1 gene/HPV16 and the HPV16/OFD1 gene junctions as biomarkers.

### Claim 17 (depends on 13)

The method of claim 13, wherein at least one specific nucleic acids sequence complementary to an integration junction between host genomic DNA and integrated HPV DNA is used for the detection by hybridization of a biomarker.

### Claim 18 (depends on 13)

The method of claim 13, wherein said HPV DNA is selected from a DNA from the group consisting of HPV strains 16, 18, 21, 33, 45, 52 and 58.

### Claim 19 (depends on 15)

A composition comprising one or more biomarkers as defined in claim 15.

### Claim 20 (depends on 19)

The composition of claim 19, wherein said one or more biomarkers is selected from the group consisting of MAPK10, PTPN13, NUDT15, MED4, ITM2B, RB1, LPAR6, RAB11A, RPL13A, ZNF341, OFD1, DHRS3, TBC1D22B, AFF3, CXCL6, PF4V1, IMMP2L, MMP12, WDR20, ALDHA1A, TPRG1, TUBD1, MAST4, LOC100132167, NFIX, CCAT1, GPR137B, RAB22A, C9orf3, MACROD2, DACH1, ATP10A, SPG11, SORD, COL4A4, GATSL1, GATSL2, MAP2, EPN1, ATXN3L, EGFL6, and MAGI2.

### Claim 21 (depends on 20)

A kit comprising standardized and purified biomarkers that hybridize with host cell DNA and with integrated viral DNA sequences, and optionally, control reagents, one or more other reagents, supplies and/or equipment useful for detecting viral integration, wherein the kit comprises one or more biomarkers of claim 20.

### Claim 22

A method of preparation of genomic DNA containing suspected integrated viral DNA from the cell sample comprising:
embedding cells into an agarose plug having an agarose concentration ranging from about 0.5 wt % to 1.5 wt %,
infusing the plugs containing the embedded cells with a proteolytic enzyme for a time and under conditions sufficient to substantially digest cellular proteins,
washing the plugs for a time and under conditions sufficient to remove episomal nucleic acids,
extracting cellular genomic DNA caught in the plugs containing or not the integrated viral DNA.

### Claim 23 (depends on 1)

A method for assessing a risk of having or developing a cervical cancer comprising: detecting or quantifying a number of integrations of HPV DNA into, or an integration pattern of HPV DNA in a sample of genomic DNA obtained from a patient or subject, thereby assessing the risk of having or developing cervical cancer, wherein said sample of genomic DNA is obtained by the method of claim 1.

### Claim 24 (depends on 23)

The method of claim 23, wherein a greater number of instances, or a greater amount of, integrated HPV DNA is indicative of a high risk of having or developing cancer or is indicative of a more aggressive or higher grade cancer compared to a patient or subject having fewer instances or lesser amounts of integrated HPV DNA.

### Claim 25 (depends on 23)

The method of claim 23, wherein a different pattern of HPV DNA integrations into genomic host DNA, compared to those in a control subject or patient, is indicative of a high risk of having or developing cancer or is indicative of a more aggressive or higher grade cancer.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 23)

The method of claim 23, wherein said HPV DNA is from a high risk or pathogenic strain of HPV selected from the group consisting of HPV strains 16, 18, 21, 33, 45, 52 and 58.

### Claim 29

(canceled)

### Claim 30 (depends on 23)

The method of claim 23, wherein said RPV is from a low risk or non-pathogenic strain of HPV that is less pathogenic than any one of HPV strains 16, 18, 21, 33, 45, 52 and 58.

### Claim 31

(canceled)

### Claim 32 (depends on 23)

The method of claim 23, further comprising detecting or quantifying a number of integrations of HPV DNA by comparison to either a patient or subject not infected with HPV, or not infected with a pathogenic strain of HPV, having no lesions or other symptoms of HPV infection, or having substantially no antibody titer or cellular immunity to HPV or to a particular HPV strain, or those in an earlier biological sample obtained from the same patient or subject.

### Claim 33

(canceled)

### Claim 34 (depends on 23)

The method of claim 23, wherein said detecting or quantifying a number of integrations is performed using molecular combing of the genomic host DNA using probes that bind to HPV DNA sequences.

### Claim 35 (depends on 23)

The method of claim 23, wherein said detecting or quantifying a number of integrations is performed using molecular combing of the genomic host DNA using probes to HPV 16, 18, 31, 33, 45 35, 39, 51, 52, 56, 58, 59, 66 and 68.

### Claim 36 (depends on 23)

The method of claim 23, wherein said detecting or quantifying a number of integrations is performed using molecular combing of the genomic host DNA using probes that bind to or cover HPV DNA L1 and L2, E1 and E2, and/or E6 and E7 sequences, wherein said probes may be labelled with the same different colored fluorescent tags.

### Claim 37 (depends on 23)

The method of claim 23, wherein the patient or subject is selected from the group consisting of:
a patient or subject having a cervical dysplasia or having a positive PAP test
a patient of subject having been infected with human immunodeficiency virus (HIV),
a patient or subject who is immunosuppressed,
a patient or subject having been exposed to diethylstilbestrol before birth,
a patient or subject being or having been treated for a precancerous cervical lesion or cervical cancer; and
a patient or subject having or being at risk of having anal, vaginal, vulvar, penile or oropharyngeal cancer.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 23)

The method of claim 23, wherein the number or pattern of HPV integrations is quantified by, or correlated, with at least one of the following:
the number of HPV integration sites in host genomic DNA or the average number of such integrations,
the size in kb of HPV DNA integrations into host genomic DNA,
the number of HPV genomes integrated at each integration site,
the presence of absence of integrated HPV DNA,
the number of HPV integration sites per cellular genome,
the average number of HPV integration sites in host cells,
the mean number of HPV genomes integrated per integration site (or the mean size of integration sites),
maximum number of HPV genomes integrated per integration site (or the maximum size of integration sites),
minimum number of HPV genomes integrated per integration site (or minimum size of integration sites), or
number of HPV genomes integrated per cellular genome.

### Claim 41 (depends on 23)

The method of claim 23, wherein the number or pattern of HPV integrations is correlated with at least one parameter of lesion status including:
normal histology (including all abnormalities without intraepithelial lesions or signs of viral infection such as metaplasia, cervicitis, decidual lesions or adenosis),
low grade (LG) lesion, corresponding to former CIN1,
high grade (HG) lesion, corresponding to former CIN2, 3 and CIS (carcinoma in situ) or AIS (adenocarcinoma in situ);
normal cervix,
Grade 1 atypical transformation (AT),
Grade 2 atypical transformation (AT),
TAG2 a if there are no major signs,
TAG2 b if there are major signs,
TAG2 c when the appearance is suggestive of invasive cancer; and/or
atypical transformation (minor or major).

### Claim 42 (depends on 23)

The method of claim 23, wherein the number or pattern of HPV integrations is correlated with at least one parameter of cytological classification including:
negative for intraepithelial lesion or malignancy,
abnormal squamous cells,
typical squamous cells (ASC),
of undetermined significance (ASC-US),
cannot exclude high-grade squamous intraepithelial lesion (ASC-H),
low-Grade Squamous Intraepithelial Lesion (LSIL),
high-Grade Squamous Intraepithelial Lesion (HSIL),
squamous cell carcinoma,
abnormal glandular cells,
atypical glandular cells (AGC): endocervical (not otherwise specified (NOS) or commented),
endometrial or not otherwise specified
atypical glandular cells, favor neoplastic: endocervical or not otherwise specified
endocervical adenocarcinoma in situ (AIS), and/or
adenocarcinoma.
